NON-SMALL CELL LUNG CANCER

This study tests whether a blood test that detects tiny bits of tumor DNA can identify lung cancer patients whose cancer might return after surgery. Those with positive results receive extra treatment (chemo plus immunotherapy) to try to eliminate any remaining cancer cells. The …

This early-stage trial tests a new vaccine called IMP3-saRNA (YMN-136) in 9 people with advanced non-small cell lung cancer who have run out of standard options. The vaccine uses self-amplifying RNA to train the immune system to attack cancer cells. The main goal is to check safe…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests whether a new drug combination (datopotamab deruxtecan plus rilvegostomig) or rilvegostomig alone works better than the current standard treatment (pembrolizumab) for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 adults with …

This study tests whether removing extra safety margins during MRI-guided radiation can safely treat non-small cell lung cancer that has spread to the brain. About 168 adults aged 18-75 with 1 to 10 brain metastases will receive this precise radiation. The goal is to see if this a…

This study tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers (like breast, stomach, lung, or ovarian cancer) that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how long that effect last…

This study tests a new drug called BNT327 given together with chemotherapy for people with advanced non-small cell lung cancer who have not had treatment before. About 1260 participants will be enrolled to see if the combination shrinks tumors, delays cancer growth, and improves …

This study tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) in 46 adults with non-small cell lung cancer that has spread to the brain and has not been treated before. The goal is to see how well the drugs shrink brain tumors. Treatment c…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in 420 adults with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated. The goal is to see if the new drug can delay cancer growth and extend life. …

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from coming back after surgery. About 868 people with stage II to IIIB non-small cell lung cancer who have had their tumor completely remov…

This study tests a drug called zanidatamab in adults with certain advanced cancers (lung, colorectal, head and neck, sarcoma, or endometrial) that have a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors. Participants receive the drug by IV every …

This early-phase trial tests a new treatment called VET3-TGI, a virus designed to infect and kill cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main go…

This study tests whether giving high-precision radiation (SBRT) to all visible cancer spots can delay the disease from getting worse in people with 1 to 5 metastases from breast or lung cancer. About 145 participants will be randomly assigned to receive either standard care alone…

This study looks at whether adding the antidepressant olanzapine to standard immunotherapy can help people with advanced non-small cell lung cancer live longer. About 156 adults with a specific type of lung cancer (EGFR mutation-negative) will either get immunotherapy alone or wi…

This study is for people with advanced non-small cell lung cancer whose cancer has started to grow again after initial immunotherapy. It tests a combination of toripalimab (an immunotherapy drug) and cryoablation (a treatment that freezes and destroys tumors). The goal is to see …

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest an…

This study tests whether adding the drug envafolimab to standard chemotherapy helps people with stage III non-small cell lung cancer that can be removed with surgery. About 390 participants will receive either envafolimab plus chemo or a placebo plus chemo before and after surger…

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with advanced MET-positive non-squamous lung cancer live longer without their cancer growing. About 300 adults who have not had prior treatment for their advanced cancer will be ra…

This study tests whether a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung cancer whose tumors have PD-L1 lev…

This study tests a new drug called TUB-040 in people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has returned. TUB-040 is designed to deliver a cancer-killing agent directly to tumor cells that have a specific marker (N…

This study tests whether giving high-precision radiation (SBRT) before chemotherapy can better control stage III non-small cell lung cancer. It involves 20 adults aged 18-75 with tumors smaller than 6 cm. The goal is to see if this combination improves local tumor control and sur…

This study tests two experimental drugs, SI-B001 and SI-B003, with or without chemotherapy, in people with advanced non-small cell lung cancer. The goal is to find a safe dose and see if the treatment shrinks tumors. About 160 adults aged 18 to 75 who have not responded to prior …

This study tests a new drug called DRP-104 in people with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2 or KEAP1). The drug works by blocking glutamine, a nutrient cancer cells need to grow. About 37 participants will receive the drug to see if it …

This study tests whether combining three anti-cancer drugs (carboplatin, paclitaxel, and ramucirumab) can shrink tumors or slow their growth in people with advanced non-small cell lung cancer. About 59 adults whose cancer worsened after initial treatment will receive this combina…

This early-stage study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck,…

This study tests the safety and effectiveness of combining two drugs, lorlatinib and ramucirumab, for people with advanced ALK-rearranged non-small cell lung cancer. About 56 participants will receive different doses to find the best one with the fewest side effects. The goal is …

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer that has spread or come back. The goal is to find the best dose and see if the combination can shrink tumors and control the disease. About 420 adults will take…

This study compares a new drug, ivonescimab, to the current standard treatment, pembrolizumab, for people with advanced lung cancer that has spread. It is for patients whose tumors have high levels of a protein called PD-L1. The goal is to see which drug helps people live longer …

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink…

This early-stage study tests a new drug called BBO-8520 in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the drug …

This study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to find a safe dose and…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that got worse after prior immunotherapy. About 630 adults will be randomly assigned to receive either the new drug or chemo every…

This study tests whether higher doses of the drug furmonertinib, alone or with chemotherapy, can control advanced non-small cell lung cancer in patients whose disease got worse after first-line treatment with a similar targeted therapy. About 60 adults with specific EGFR gene mut…

This phase 3 study tests whether adding the experimental drug BL-B01D1 to the standard targeted therapy osimertinib works better than osimertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 720 adults with locally advanced or metasta…

This early-phase trial tests a new drug called MDX2001 in about 285 adults with advanced solid tumors (cancers that have spread). The main goals are to check the drug's safety and find the right dose. Researchers will also see if it shrinks tumors. This is not a cure, but it may …

This early-phase study tests whether adding a short course of high-dose radiation before standard chemotherapy and immunotherapy can make borderline resectable non-small cell lung cancer easier to remove with surgery. About 18 adults will receive three doses of radiation followed…

This study tests whether giving a new immunotherapy drug (QL1706) along with standard chemotherapy before surgery can help shrink tumors in people with a certain type of lung cancer (non-small cell lung cancer). About 30 adults with stage IIB to IIIB lung cancer will receive the …

This study follows up to 100 people with cancers like melanoma, lung cancer, or rare tumors who are already benefiting from treatment with dabrafenib and/or trametinib. The goal is to monitor long-term safety and side effects while patients continue their medication. Participants…

This study tests a new treatment for people with advanced cancers that have spread and express a protein called NY-ESO-1. Patients receive a single infusion of their own immune cells that have been genetically modified to recognize and attack cancer cells. The goal is to see if t…

This study tests if adding an extra cancer drug to the standard immunotherapy (cemiplimab) and chemotherapy helps shrink early-stage lung cancer more before surgery. About 120 adults with stage II-IIIB non-small cell lung cancer will be randomly assigned to receive either the two…

This early-stage study tests a new drug called IDE034 in about 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink …

This study tests whether adding the experimental drug SKB264 to the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV disease w…

This study tests whether early, specialized heart monitoring and care can reduce heart problems in people with advanced lung cancer who are getting chemoradiation and immunotherapy. About 524 adults with stage III non-small cell lung cancer will be randomly assigned to receive ei…

This study tests a drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to check safety and see if the drug shrinks tumors. About 764 participants with cancers like ovarian, lung, breast, or endometrial cancer will t…

This study tests an experimental drug called STK-012, alone or with standard chemotherapy, in people with advanced solid tumors, especially a type of lung cancer called non-small cell lung cancer (NSCLC). The goal is to see if STK-012 is safe and can shrink tumors better than cur…

This study compares two drug combinations for people with advanced non-small cell lung cancer that has spread. One group gets ivonescimab plus chemotherapy, the other gets pembrolizumab (Keytruda) plus chemotherapy. The goal is to see which combination helps people live longer an…

This study is for people with advanced, gene-mutated non-small cell lung cancer who have not yet started treatment. Researchers want to see if giving radiation to the main lung tumor before starting daily targeted pills (TKI) can keep the cancer from growing longer. About 34 part…

This study tests a new drug, telisotuzumab vedotin, against a standard chemotherapy (docetaxel) in adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has a marker called c-Met. About 698 participants worldwide will be randomly assigned to receiv…

This study tests whether the drug cemiplimab, given after surgery, can delay the return of non-small cell lung cancer in patients with stage II-IIIA. About 390 participants will either receive cemiplimab infusions or be observed without treatment. The goal is to see if the drug i…

This early-phase study tests a new drug called GNC-077 in about 20 people with advanced lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have a tumor that can …

This early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …

This study tests a drug called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The drug works by blocking certain proteins that help cancer grow. About 18 adults with stage IIIB or IV lung cancer who …

This early-phase study tests whether adding carotuximab to the standard drug osimertinib is safe and tolerable for people with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to treatment. About 60 participants will receive the combination to find the…

This study tests a new drug, CKD-703, for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to cancer cells that have a specific ma…

This early-stage study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This early-stage study tests a new drug called tolododekin alfa combined with an immunotherapy for people with advanced non-small cell lung cancer. About 60 participants will join, including those whose cancer worsened after standard treatments and those who have not yet been tre…

This study tests a daily pill called sunvozertinib against a placebo in 360 people with a specific type of lung cancer (stage IB-IIIA non-small cell) that has certain gene changes (EGFR exon20ins or PACC). All participants have had their tumor completely removed by surgery. The g…

This study tests a treatment plan for people with stage III lung cancer. First, patients get three rounds of chemotherapy plus the immunotherapy drug atezolizumab. Then, depending on how the tumor responds, they either have surgery followed by more atezolizumab, or radiation ther…

This study tests two experimental drugs (DZD9008 and AZD4205) together in people with advanced non-small cell lung cancer that has EGFR mutations and has stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink tumors. About 90 adult…

This study tests a new approach for people with stage II to III non-small cell lung cancer that can be surgically removed. Before surgery, participants receive low-dose radiation, a precise high-dose radiation treatment (SBRT), and a combination of immunotherapy (tislelizumab) an…

This early-stage study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study tests an experimental drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers that have not responded to other treatments. The main goal is to see if the drug can shrink tumors, while also checking for side eff…

This study tests a new drug (ES102) combined with an immunotherapy (toripalimab) in 40 people with advanced non-small cell lung cancer that has not responded to prior treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Participants must …

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This study tests whether adding a healthy gut bacteria (EXL01) to the immunotherapy drug nivolumab can help control advanced non-small cell lung cancer that has stopped responding to standard treatments. About 21 adults whose cancer progressed after prior therapies will receive t…

This study tests whether combining a targeted drug (adagrasib) with precise radiation (stereotactic radiosurgery) can better control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive …

This study tests a new drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific gene change (STK11 mutation). The goal is to find the safest dose and see if the combination can shrink tumors. About 126 adults with…

This study looks at whether adding a precise type of radiation (stereotactic radiosurgery) to standard drug treatments can better control brain tumors in people with melanoma or non-small cell lung cancer that has spread to the brain. About 180 participants with newly diagnosed, …

This study tests whether adding ivonescimab to standard chemotherapy (docetaxel) helps adults with advanced non-small cell lung cancer whose disease has worsened after prior immunotherapy. About 536 participants will receive either the combination or a placebo plus chemotherapy. …

This study tests whether adding a short course of the MEK inhibitor mirdametinib to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer whose PDL1 level is below 50%. About 24 participants will first help find the bes…

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with another drug (osimertinib), can shrink tumors before surgery in people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). About 60 adults with early-stage, operable cance…

This study is for people with a type of lung cancer that has spread to only a few places in the body and has a specific gene change. Participants will either continue taking their targeted therapy pills alone or also receive focused radiation to the cancer spots. The goal is to s…

This study tests whether a combination of two drugs (trastuzumab deruxtecan and pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced non-small cell lung cancer that has high HER2 levels and low PD-L1. About 686 adults who have not had…

This early-stage study tests a new treatment using a patient's own immune cells, modified in a lab to recognize and attack cancer cells with a specific KRAS mutation (G12D). It is for adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not respond…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses the patient's own T cells, which are modified in…

This study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…

This study tests a treatment using immune cells taken from a patient's own lung tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The goal is to see if this approach can stop or slow the cancer from growing for at least 6 months. The t…

This study tests an experimental drug, LY3962673, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and see if it can shrink tumors, both alone and…

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (ctDNA positive) after initial treatment with osimertinib. Researchers want to see if adding a second drug, sacituzumab tirumotecan, can improve outcomes. Abo…

This early-phase study tests a new treatment called PeptiCRAd-1, a virus designed to train the immune system to attack cancer cells, combined with the immunotherapy drug pembrolizumab. About 15 adults with certain advanced solid tumors (like melanoma, lung cancer, or sarcoma) wil…

This study tests an experimental drug called MCLA-129 in people with advanced solid tumors, including lung, head and neck, and colorectal cancers that have stopped responding to standard treatments. The drug is a bispecific antibody designed to target two cancer-related proteins …

This study tests a new combination of two drugs, DZD6008 and sunvozertinib, in adults with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the combination is safe and can shrink or control tumors. About 200 participants will take part i…

This study tests whether adding radiation therapy after surgery, along with immunotherapy, can help keep non-small cell lung cancer from returning in people whose cancer has spread to multiple lymph nodes. About 60 adults aged 18 to 75 will take part. The main goal is to see how …

This early-phase study tests a new drug called AZD6750, which is designed to guide the immune system to attack cancer cells. It is for adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that have not responded to other treatments. The study will check …

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with non-small cell lung cancer that can be removed by surgery. The goal is to see if the combination can eliminate cancer cells before and after surgery, improving long-term outcomes. A…

This study tests whether adding a targeted drug (MK-1084) to standard immunotherapy after surgery can help prevent KRAS G12C-mutant lung cancer from coming back. About 400 adults with stage IIA-IIIB non-small cell lung cancer who have had complete tumor removal will be randomly a…

This study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) in people with advanced lung cancer that has specific uncommon genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease…

This expanded access program provides zidesamtinib, an investigational drug, to adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have already tried at least one ROS1-targeted therapy and have no satisfactory alternatives. The goal is to offe…

This early-phase study tests a special immune cell therapy (CD40L TIL) combined with the drug nivolumab for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). The goal is to see if this treatment is safe and can shrink tumor…

This early-phase study tests a new investigational drug called azirkitug, alone or combined with other drugs, in adults with advanced solid tumors such as lung, head/neck, colorectal, and breast cancers. The main goals are to check safety, side effects, and how the drug moves thr…

This expanded access program offers the investigational drug neladalkib to adults with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have no satisfactory treatment options and cannot join a clinical trial. Participants must have already t…

This study tests a lower dose of the targeted therapy osimertinib in people with advanced EGFR-positive non-small cell lung cancer. The goal is to see if the lower dose can still control the cancer while causing fewer side effects. About 58 adults with specific EGFR mutations wil…

This study tests a new drug called volrustomig combined with other cancer treatments in people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults with specific types of lung cancer will take part.

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapies. OBX-115 uses a patient's own tumor-fighting immune cells (TILs) that have been modified to produc…

This study tests whether adding the experimental drug SHR-A2009 to the standard pill aumolertinib works better than aumolertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 576 adults who have not had prior treatment for their advanc…

This study tests a drug called lazertinib, given alone or with chemotherapy, before surgery for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). The goal is to see if the treatment shrinks the tumor enough to improve surgery results. About 160…

This study tests whether adding the drug tarlatamab to standard radiation is safe and effective for cancers that have a protein called DLL3. About 30 adults with cancers like melanoma, lung cancer, or glioblastoma will receive the combination. The goal is to find the best timing …

This study tests a new treatment plan for veterans with advanced lung cancer that cannot be removed by surgery. Participants will receive chemotherapy and immunotherapy before radiation therapy. The goal is to see if this approach helps control the cancer longer and is safe for p…

This study is the first time the experimental drug KK2269 is being tested in people. It aims to check the safety of KK2269 given alone or with the chemotherapy drug docetaxel. The trial involves about 101 adults with advanced solid tumors (like stomach, lung, or esophageal cancer…

This study tests the safety of a new drug called ivonescimab when given with standard chemotherapy and precise radiation (SRS) to people with non-small cell lung cancer that has spread to the brain. About 53 adults will join to find the best dose with the fewest side effects, and…

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 protein, making it harder to treat. Researchers want to see if using two different immunotherapy drugs together with chemotherapy works better than just one immunotherapy drug with chem…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer that has certain gene changes (RET, ROS1, NTRK fusions, or increased MET or AXL activity). The goal is to see if the drug can shrink tumors and stop them from growing. About 86 participants …

This early-phase study tests a new drug called PT0511 in adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works alone or w…

This study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people whose non-small cell lung cancer, melanoma, or kidney cancer has been surgically removed. The goal is to see how the body processes HLX17 compared to Keytruda, and to check fo…

This study tests whether adding nelmastobart to the chemotherapy drug docetaxel can help people with advanced non-small cell lung cancer whose cancer has stopped responding to or cannot tolerate standard platinum-based chemo or immunotherapy. About 62 adults with a specific marke…

This study tests a new drug (YL201) combined with ivonescimab in 260 adults with advanced solid tumors, including lung cancers. The goal is to see if the combination is safe and can shrink tumors. Participants must have good organ function and not be eligible for local curative t…

This early-phase study tests whether adding DNA damage repair inhibitors to standard radiation therapy is safe for people with stage IIB or III non-small cell lung cancer who cannot have surgery or chemo-radiation. About 200 participants will receive the drug combination, followe…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study tests whether adding a precise, high-dose radiation treatment to the liver (L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either standard dru…

This study tests whether a new drug called rilvegostomig, combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced squamous non-small cell lung cancer that has spread. About 880 adults whose tumors show a spe…

This study tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemotherapy and immunotherapy can help people with advanced squamous non-small cell lung cancer live longer. About 851 adults with stage IV lung cancer will receive pembrolizumab plus chem…

This study is for people with early to mid-stage non-small cell lung cancer that can be removed with surgery. Before surgery, participants will receive a combination of low-dose radiation and two immunotherapy drugs (ipilimumab and nivolumab). The goal is to see if this treatment…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This early-stage study tests a new, highly focused type of radiation called hypervision proton surgery for people with early-stage non-small cell lung cancer. The goal is to see if a single, large dose of radiation can safely control the tumor. About 12 participants will receive …

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to an existing immunotherapy (atezolizumab) can help control several advanced solid tumors, including pancreatic, lung, bladder, and triple-negative breast cancer. About 247 adults with t…

This study tests whether a focused ultrasound device can safely open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. Participants will receive standard immunotherapy while some also get the ultrasound treatment. The goal is to see i…

This study tests whether a special type of radiation (SFRT) combined with the immunotherapy drug tislelizumab and standard chemotherapy can shrink stage III lung cancer enough to allow surgery. About 30 adults with initially unresectable non-small cell lung cancer will receive th…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) in people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various cancers, inclu…

This early-phase study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and can shrink tumors, either alone or with other cancer treatments. About 340 adults whose cancer has …

This study tests a new drug, ANS02, in about 294 adults with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check safety and find the right dose, while also seeing if the drug can shrink tumors. Participants must have tried other trea…

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer that has a high level of a protein called c-Met). About 150 participants will be randomly assigned to one of three different dose …

This study is testing whether a diet rich in fermented foods (like yogurt, kimchi, and sauerkraut) can help people with rectal cancer or lung cancer respond better to their standard treatments. About 54 participants will either follow this special diet or continue their usual eat…

This study tests whether adding new drugs, like patritumab deruxtecan, to standard immunotherapy (pembrolizumab) with or without chemotherapy can better control advanced non-small cell lung cancer. About 90 people with untreated stage IV NSCLC will participate. The goal is to see…

This study tests a new way to perform lung cancer surgery for early-stage non-small cell lung cancer. Doctors use a 3D computer model (Synapse 3D) and a special dye (indocyanine green) to see the exact part of the lung that needs removal. The goal is to remove only the diseased s…

This phase 3 trial tests whether using MRI scans to guide radiation therapy, along with chemotherapy and immunotherapy, can reduce lung damage and improve outcomes for people with locally advanced non-small cell lung cancer. About 490 participants will be randomly assigned to rec…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and infuse th…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if…

This study tests whether adding an experimental drug (Dato-DXd) to the standard pill osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 582 adults with stage IIIB/IV non-small cell lung cancer will receive either osimert…

This study tests whether a new two-drug combination (IN10018 and D-1553) works better than standard chemotherapy plus immunotherapy for people with a specific genetic type of advanced lung cancer (KRAS G12C mutation). About 400 adults who have not had prior treatment for their ad…

This study tests whether a new targeted therapy (divarasib) combined with an immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation). About 600 adults who have…

This study tests several new drug combinations given before and after surgery for people with early-stage non-small cell lung cancer. The goal is to see if these combinations are safe and help destroy more cancer cells. About 630 adults with stage II to IIIB lung cancer will take…

This study is for people with stage III non-small cell lung cancer who have already had chemotherapy and radiation. Researchers want to see if adding another drug (tremelimumab) and extra chemotherapy to the standard drug (durvalumab) can lower the amount of cancer DNA in the blo…

This study is testing whether combining two drugs, envafolimab and lenvatinib, can shrink tumors in people with advanced solid tumors (like lung, kidney, or liver cancer) who have run out of standard options. About 170 adults will receive the combination to find the best dose and…

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive standard immunotherapy plus liver radiation. The goal is to s…

This study tests an experimental drug called TQB2102 for people with advanced non-small cell lung cancer that has a HER2 gene abnormality. The drug works like a guided missile, delivering a strong cancer-killing agent directly to tumor cells. The trial will enroll about 270 adult…

This phase 3 study compares a new drug, NVL-655, to the current standard alectinib in people with ALK-positive advanced non-small cell lung cancer who have not had prior treatment. The main goal is to see if NVL-655 can delay cancer growth or death longer than alectinib. About 45…

This early-phase study tests a new drug called anvumetostat, alone or with other treatments, in adults with advanced lung or chest cancers that have a specific genetic deletion (MTAP-deleted). The main goals are to find the safest dose and understand side effects. About 500 parti…

This study tests whether removing extra safety margins during precise radiation therapy can lower breathing side effects for people with early-stage lung cancer or a few lung tumors that have spread from other cancers. About 130 participants will receive either standard or margin…

This study compares two types of minimally invasive surgery for early-stage non-small cell lung cancer: robot-assisted (RATS) and video-assisted (VATS). About 1,124 patients will be randomly assigned to one of the two procedures. The main goal is to see if robot-assisted surgery …

This early-stage trial tests a new treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. …

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried other tr…

This study looks at whether adding surgery or radiation to the main tumor can help people with advanced EGFR-mutant lung cancer who have already responded to a combination of osimertinib and chemotherapy. About 70 adults will receive local therapy and be followed to see how long …

This study tests a new approach for people with advanced non-small-cell lung cancer whose disease has worsened after initial chemotherapy and immunotherapy. Participants receive an experimental virus (Olvi-Vec) followed by chemotherapy plus an immunotherapy drug, or the standard …

This early-stage trial tests a new radioactive drug, [225Ac]-FPI-2068, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see how the drug spreads in the body. About 70 people with cancers like lung, colon, …

This early-phase study tests a new drug called PRTH-101, alone or with pembrolizumab, in adults with advanced or metastatic solid tumors (like lung cancer). The main goals are to check safety, find the best dose, and see how the drug works in the body. About 270 participants will…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have lost a specif…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if CP-383 can slow or stop cancer growth and to find the safest dose. About 150 participants will take the drug daily and ha…

This early-phase study tests a new drug called 177Lu-RAD204, which combines a targeting antibody with a radioactive particle to seek out and attack cancer cells. The trial involves 30 adults with advanced solid tumors like lung, breast, or skin cancer that have not responded to o…

This early-phase study tests a new drug, LNCB74, in about 145 people with advanced solid tumors (ovarian, breast, lung, and others). The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the best dose for futur…

This study tests whether adding a new drug, GEN-725, to the existing drug dositinib is safe and works better for people with advanced lung cancer that has a specific EGFR gene mutation. About 110 adults aged 18-75 will take part. The goal is to shrink tumors and control the disea…

This study tests a new surgical technique called septum-guided segmentectomy for people with early-stage non-small cell lung cancer (tumors 2 cm or smaller) located deep in the lung. The goal is to remove the cancer completely while preserving as much healthy lung as possible, wh…

This study tests whether adding targeted radiotherapy to the usual drug treatment can lower the chance of lung cancer growing or spreading. It involves 320 adults with stage IV non-small-cell lung cancer whose disease has started to progress in a limited number of spots while on …

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This study tests a new drug called SIM0610 in adults with advanced solid tumors (cancers that have spread). The main goals are to check safety and find the right dose. About 260 people with certain cancers like lung, colon, head and neck, or liver cancer can join. The study has t…

This study looks at whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide when to add chemotherapy to standard immunotherapy for people with advanced lung cancer. About 230 participants will receive pembrolizumab, and if their ctDNA levels don't drop…

This early-stage trial tests a new mRNA treatment called BNT116 for people with advanced non-small cell lung cancer. The study aims to find safe doses of BNT116 when used alone or with other cancer drugs. About 320 participants with different stages of lung cancer will take part.…

This study compares two treatments for early-stage non-small cell lung cancer in patients who are high-risk for surgery. One group gets a type of radiation called SAbR, the other has surgery to remove the tumor. The goal is to see which approach helps patients live longer and wit…

This study tests several different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. Participants receive treatment before and after surgery based on specific biomarkers in their tumor. The goal is to see if these targeted t…

This early-stage study tests a new drug called OCT-598 in about 51 adults with advanced solid tumors (breast, lung, prostate, head/neck, or stomach cancer). The main goals are to check safety, find the best dose, and see how the drug works alone or with standard treatments. Parti…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This study tests a drug called TolueneSulfonamide, injected directly into the chest, to see if it safely reduces fluid buildup in people with lung cancer. About 105 adults with malignant pleural effusion and trouble breathing will take part. The goal is to control the fluid and i…

This study tests a new oral drug, TNG456, in people with advanced solid tumors that lack a gene called MTAP. The drug aims to slow or stop cancer growth by blocking a protein these tumors rely on. The trial has two parts: first finding the safest dose, then testing how well it wo…

This early-stage study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has certain EGFR gene changes. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors. About 140 adults whose c…

This early-phase study tests a new drug, KIVU-107, in about 76 adults with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goal is to find the…

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. Participants receive the drug and are monitored for side effects a…

This study is for people with early-stage non-small cell lung cancer. After standard treatment, a blood test checks for leftover cancer DNA, which raises the risk of the cancer coming back. If the test is positive, participants receive the drug durvalumab to try to lower that DNA…

This study combines a special nanoparticle (AGuIX) with precise, MRI-guided radiation to treat hard-to-reach lung tumors and advanced pancreatic cancer. The goal is to see if adding these nanoparticles makes radiation more effective at controlling tumors without increasing side e…

This study tests whether adding the drug BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). About 25 participants will receive both t…

This study tests a new drug called HMBD-501 in people with advanced melanoma, lung, or breast cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 180 adults will take part in two phases: first t…

This study tests a drug called iruplinalkib in people with a specific type of advanced lung cancer (ALK-positive) that has stopped responding to a previous treatment called lorlatinib. The goal is to see how well iruplinalkib controls the cancer and what side effects occur. About…

This study is for people with advanced or metastatic solid tumors, including non-small cell lung cancer, who have not responded to other treatments. It tests a combination of two drugs: HLX43 (an antibody-drug conjugate targeting PD-L1) and serplulimab (an immunotherapy). The goa…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the tumors. About 350 participants will take part in this early-phase trial.

This early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with untreated metastatic non-squamous non-small cell lung cancer. …

This study tests a drug called SAR445877 in people with advanced non-small cell lung cancer that has gotten worse after immunotherapy. The goal is to see if the drug can help control the cancer. About 29 adults will take part, and the main focus is on safety and side effects.

This study tests whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to standard immunotherapy can help people with advanced non-small cell lung cancer who are too weak for aggressive treatment. About 120 participants will receive either real or sh…

This early-stage study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors like bladder, breast, lung, or cervical cancer that have not responded to prior treatments. The main goals are to find the safest dose and see if …

This study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who have done well on initial immunotherapy but still have cancer DNA in their blood. About 70 participants will receive either the new combi…

This phase 3 trial tests whether giving the immunotherapy drug durvalumab after surgery and initial chemo-immunotherapy can delay or prevent lung cancer from returning in people with stage IIB-IIIB non-small cell lung cancer. About 290 participants will receive either durvalumab …

This study tests whether adding the experimental drug MK-1084 to standard immunotherapy (pembrolizumab) helps people with advanced KRAS G12C-mutant non-small cell lung cancer live longer or delay tumor growth. About 600 participants will receive either the combo or pembrolizumab …

This study tests a new drug called dositinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The goal is to find a safe dose and see if the drug can shrink tumors. About 153 adults aged 18-75 who have already tried other tre…

This study tests whether adding a nitroglycerin patch (a heart medication) to standard radiation therapy can better shrink brain tumors in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. About 74 adults will be ran…

This study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer that has spread. About 1,410 participants will be randomly ass…

This study tests a daily pill called sunvozertinib in 34 adults with advanced non-small cell lung cancer that has certain uncommon EGFR gene changes. Participants have not had prior cancer treatment. The main goal is to see how many people's tumors shrink, and how long that lasts…

This study tests a new drug called pumitamig combined with standard chemotherapy for people with advanced non-small cell lung cancer that has worsened after initial treatment. About 60 participants will receive the combination to see if it is safe and helps shrink tumors. The goa…

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. Participants receive specially designed natural killer (NK) immune cells that target two cancer markers at once. The goal is to see if this approach …

This study tests an experimental drug called SHR-1826 in 90 people with advanced or spreading non-small cell lung cancer who have already tried other treatments. Participants receive the drug by IV every three weeks. The goal is to see if the drug can shrink tumors and how safe i…

This study tests whether adding a second immunotherapy drug (domvanalimab) to the standard drug durvalumab can better control stage III lung cancer that hasn't grown after chemoradiation. About 860 adults with a specific type of lung cancer will receive either the combo or durval…

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 adults with stage 3 or 4 lung cancer will t…

This study tests a new treatment for people with a specific type of lung cancer (EGFR mutation-positive NSCLC) that has spread to the brain and its lining. The treatment combines a targeted drug (furmonertinib) with chemotherapy injected into the spinal fluid and precise radiatio…

This study tests a new drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug can shrink tumors. About 251 participants will take the drug by mouth,…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 470 adults will take part.

This early-stage study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors, including pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see …

This study tests an experimental drug called sutetinib maleate in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors or slow cancer growth. About 66 adults will take the capsule and be monitored for r…

This study tests a new combination of drugs (calderasib plus pembrolizumab) against standard chemotherapy plus pembrolizumab for people with a specific genetic type of advanced non-small cell lung cancer (KRAS G12C mutation). The goal is to see if the new combo helps people live …

This study looks at the best order to give EGFR-inhibitor drugs to people with advanced lung cancer that cannot be cured. About 200 participants will be assigned to different treatment sequences, and researchers will track how long the cancer stays controlled, side effects, and q…

This study compares a new drug, taletrectinib, to the standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not had targeted therapy before. About 194 participants will be randomly assigned to take one …

This study tests a new drug called YL202 combined with other cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to find a safe dose and see if the combination shrinks tumors. About 414 adults aged 18-75 who have tried standard tr…

This study tests a new drug, ASP5834, for people with advanced solid tumors that have certain changes in the KRAS gene. The drug is given alone or with another drug (panitumumab) for colorectal cancer. The main goals are to find a safe dose and check for side effects. About 364 a…

This study tests whether combining one chemotherapy drug with the immunotherapy pembrolizumab is safe and effective for people with advanced non-small cell lung cancer who have limited physical activity (ECOG PS 2). About 28 participants will receive this treatment as their first…

This early-stage study is testing an experimental drug called CGT4255 in about 100 adults whose advanced solid tumors have specific genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to check safety, find the best dose, and see if the drug shrinks tumo…

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study tests a combination of two drugs—tulmimetostat and pembrolizumab—in people with advanced non-small cell lung cancer whose cancer has worsened after initial treatment. The goal is to see if the combination can shrink tumors or slow cancer growth. About 66 veterans will …

This study tests whether adding a special type of radiation (SFRT) to standard treatment can help control non-small cell lung cancer that has started to grow again after initial therapy. About 25 adults with up to 5 progressing tumors will receive SFRT on those spots while contin…

This study tests a new drug, WSD0922-FU, in 40 adults with advanced non-small cell lung cancer that has a specific genetic change (C797S mutation) and has stopped responding to the standard first treatment, osimertinib. The main goal is to see how many patients' tumors shrink or …

This study tests the drug fingolimod (currently used for multiple sclerosis) in people with advanced non-small cell or small cell lung cancer whose cancer has worsened after standard treatments. The goal is to see if the drug is safe and can shrink tumors or slow cancer growth. A…

This study tests whether combining ivonescimab with either Dato-DXd or osimertinib is safe and works for people with advanced EGFR-mutant non-small cell lung cancer that stopped responding to previous treatments. About 66 adults will join to find the best dose and check if tumors…

This study tests whether the drug anlotinib can help prevent lung cancer from coming back in patients who still had cancer cells after surgery and chemotherapy. About 64 adults with stage IIA-IIIA non-small cell lung cancer will take anlotinib capsules. The main goal is to see ho…

This study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and shrinks tumors. About 320 adults who have not had prior treatment…

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …

This study is for people with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. It tests a new drug called AOH1996, which works by blocking certain enzymes that cancer cells need to grow. The main goals are to find the be…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. About 162 adults will rece…

This study tests a new treatment for people with non-small cell lung cancer who have had surgery. Doctors take immune cells from the removed tumor, grow them in a lab, and give them back to the patient. The goal is to see if these cells can keep the cancer from coming back. About…

This study tests a new combination of two drugs (HLX43 and serplulimab) given before surgery to people with non-small cell lung cancer. The goal is to see if the drugs can shrink tumors and improve treatment results. About 60 adults with stage II-IIIB lung cancer will participate…

This early-phase study tests a vaccine that targets specific KRAS mutations in advanced non-small cell lung cancer. About 12 participants will receive the vaccine alongside standard chemotherapy and immunotherapy drugs (nivolumab and ipilimumab). The main goal is to check safety …

This study tests a new drug called sunvozertinib combined with chemotherapy in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard targeted therapy. About 40 adults will receive the combination to …

This study tests whether a personalized cancer vaccine (intismeran) alone or combined with an immunotherapy (pembrolizumab) can prevent non-small cell lung cancer from returning after surgery. About 876 adults with high-risk stage I lung cancer that was fully removed will be rand…

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment for advanced disease will take part. The goal is to see if …

This study tests a new oral drug, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The trial will first find the safest dose, then check if the drug shrinks tumors when used alone or with other ca…

This study tests whether adding SKB264 to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer getting worse. About 420 adults who have not had prior treatment for advanced disease will be randomly assigned to receive e…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests whether adding a traditional Chinese herbal decoction called HGXJT to standard immunotherapy can better control non-small cell lung cancer that has spread to the bones. About 82 adults with this type of cancer will receive either the herbal medicine or a placebo …

This study tests a new drug, izalontamab brengitecan, against standard chemotherapy for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has gotten worse after taking targeted pills called EGFR tyrosine kinase inhibitors. About 596 adults …

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests whether a transplant of healthy gut bacteria (from donor stool) combined with the immunotherapy drug pembrolizumab can help people with advanced lung cancer that has stopped responding to standard treatments. About 26 participants will receive the bacteria transp…

This study is testing a type of radiation called stereotactic body radiation therapy (SBRT) for people with lung cancer or cancer that has spread to the lung. The treatment delivers high doses of radiation in just 3 to 10 sessions over 1 to 2 weeks. Researchers want to see how we…

This study compares two drug combinations for people with advanced squamous non-small cell lung cancer who have not had treatment before. About 574 participants will receive either RC148 or tislelizumab, both combined with standard chemotherapy. The goal is to see which combinati…

This study tests a new two-drug combination (ZG005 and gecacitinib) in people with advanced non-small cell lung cancer that has not responded to standard PD-1/L1 therapy. The goal is to see if the combination is safe and can shrink tumors. About 50 adults aged 18 to 75 will take …

This study tests whether giving the drug trastuzumab deruxtecan before routine surgery can shrink tumors in people with a specific type of lung cancer (HER2-amplified or HER2-mutated non-small cell lung cancer). About 14 adults with stage II to IIIB lung cancer will receive the d…

This study tests whether adding a special surgical glue (Progel Platinum) to the standard stapling method during lung cancer surgery can help patients recover faster. About 160 adults having keyhole surgery for non-small cell lung cancer will take part. The main goal is to see if…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study tests a new drug called andamertinib, alone or with chemotherapy, for people with advanced lung cancer that has certain rare gene changes (atypical EGFR mutations). About 40 participants who have not had prior treatment will be randomly assigned to receive the drug, th…

This study tests a combination of SKB264 and KL-A167, with or without chemotherapy, in 110 adults with advanced non-small cell lung cancer that has spread. The goal is to see if the combo can shrink tumors or slow the disease, while checking for side effects. Participants must ha…

This study tests an experimental drug, telisotuzumab adizutecan, against standard care in about 430 adults with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened after using a third-generation targeted therapy. The go…

This study tests whether using a protein-based test to choose treatment can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard therapy …

This study tests a new drug called AU-007 in people with advanced solid tumors (like melanoma or lung cancer) that cannot be removed by surgery or have spread. The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007…

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. About 278 adults will receive different treatment mixes to see if they shrink tumors and are safe. The goal is to find better ways to control the disease and improve…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can better prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and i…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from returning after surgery in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. About 400 adults who have had their tumor completely removed…

This study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…

This phase 3 study tests whether adding the diabetes drug metformin to standard targeted therapy (tyrosine kinase inhibitors) can help control advanced non-small cell lung cancer with EGFR mutations. About 312 adults with stage IIIB or IV lung cancer will receive either metformin…

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This study looks at whether giving radiation to the chest after surgery can help people with stage III lung cancer who still have some cancer left after chemo and immunotherapy. About 118 adults will be randomly assigned to get either standard follow-up care or additional radiati…

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This early-phase study tests a new oral drug, DO-2, in adults with advanced solid tumors (like lung cancer) that have a specific MET gene change and no standard treatment options left. The main goal is to check the drug's safety and find the right dose. About 55 participants will…

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced non-small cell lung cancer or nasopharyngeal carcinoma that has spread. The main goal is to see if the treatment is safe and if it shrinks tumors. Researchers will enroll about 121 adul…

This early study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. The main goal is to check if the drug is safe and how it moves through the body, …

This early-phase trial is testing a special PET imaging agent that targets a protein called IFN-gamma to see if it can help detect non-small cell lung cancer and show how well the cancer responds to immunotherapy. Six adults with newly diagnosed lung cancer will receive the imagi…

This study tests a special microscope (CLE) that lets doctors see lung tissue in real time during a biopsy. The goal is to quickly tell if a suspicious spot is non-small cell lung cancer and what type it is. About 70 adults getting a standard lung biopsy will also have CLE imagin…

This study is testing a new type of PET scan that uses a special probe (68Ga-TOI-1) to find lung tumors more accurately. The probe targets a protein called CDH3, which is only found on cancer cells. Researchers will compare this new scan with the standard FDG-PET scan in 80 adult…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and compare them to known tumor DNA. The goal is to see if this n…

This early-phase study is testing a new radioactive tracer for PET scans that may better detect non-small cell lung cancer that has spread to the brain. About 20 adults with this type of lung cancer and brain metastases will receive the tracer and undergo imaging. The goal is to …

This early study is testing a new imaging agent called FL-261 to see if it can safely and accurately detect and stage several types of cancer, including lung, colorectal, and head & neck cancers. The agent targets a protein (c-MET) found on many cancer cells but not on most healt…

This study is testing a new type of PET/CT scan that uses a special tracer called 18F-T2 to find cancers that have high levels of a protein called CAIX. About 200 adults with cancers like kidney, bladder, lung, or breast cancer will get this scan to see if it works better than th…

This study tests if a special PET scan (FAPI-PET) and a fluorescent dye can help doctors find leftover lung cancer during surgery after standard treatment. About 200 people with stage II-IIIB non-small cell lung cancer will get the scan and dye before and during surgery. The goal…

This study tests a new way to perform lung cancer surgery for people with early-stage non-small cell lung cancer. Surgeons use a special dye and a robotic camera to see which part of the lung contains the tumor, so they can remove only that small piece instead of an entire lobe. …

This study tests whether a supervised exercise and breathing program (pulmonary rehabilitation) can improve shortness of breath and quality of life in people with advanced non-small cell lung cancer. Half of the 85 participants will receive 8 weeks of rehab, while the other half …

This study looks at whether a simple exercise program is practical and helpful for people with lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient and caregiver) will take part. The goal is to see if the program improves qual…

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better than standard radiation and whether it helps the immune system attack cancer cells. Abo…

This study tests whether a new form of megestrol acetate can help people with advanced lung cancer maintain their appetite and body weight while undergoing chemotherapy and radiation. About 134 participants will receive either the drug or a placebo alongside standard cancer treat…

This study tests a 12-week home-based physical activity coaching program for people who had surgery for early-stage lung cancer. Participants wear a Fitbit and get personalized step goals and coach support via a smartphone app. The goal is to see if this program helps patients be…

This study tests whether structured online singing training can improve physical function, reduce symptoms, and boost quality of life in people who had surgery for early-stage lung cancer 6 to 18 months ago. About 100 participants will be randomly assigned to either online singin…

This study tests whether a special immune-boosting nutrition plan can lower the chance of severe throat inflammation (esophagitis) in lung cancer patients receiving chest radiation. About 121 adults with lung cancer will be randomly assigned to get either the immunonutrition or s…

This early-stage study tests whether adding Tumor Treating Fields (TTFields) to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About 30 participants will receive TTFields alongside their us…

This study compares two ways to deliver breathing exercises before and after lung cancer surgery: in-person sessions with a physiotherapist versus using a smartphone app (Fissios App) alongside those sessions. The goal is to see if the app helps reduce complications like infectio…

This study tests whether a supervised exercise program is safe and possible for people with stage II or III lung cancer who are receiving radiation and chemotherapy. Ten participants will do breathing exercises, walking or cycling, and light strength training during their treatme…

This study compares how patients feel after two minimally invasive surgeries for early-stage lung cancer: removing just the tumor (segmentectomy) versus removing the whole lobe (lobectomy). Researchers will track 180 patients for one year, asking about shortness of breath, physic…

This study tests whether a mobile app that guides patients and their caregivers through yoga exercises is safe and easy to use. It includes 60 people with lung or esophageal cancer who are getting radiation therapy, plus a family caregiver. The goal is to see if the app is a prac…

This study looks at immune cells (T cells) in tumor samples from 1,100 people with cancers like head and neck, ovarian, cervical, lung, and brain cancer. Researchers want to understand how these cells behave, especially a protein called PD-1. No new treatments are tested—only sam…

This study looks at whether a lab-made model of a patient's own lung cancer cells can help doctors choose the most effective drugs. Researchers will compare the model's predictions with how the patient actually responds to treatment. The goal is to see if this approach can improv…

This study looks at 300 people with early-stage lung cancer to understand why some tumors grow differently. Researchers will analyze genes, immune cells, and other markers from tumor samples. The goal is to find better ways to predict cancer return and identify new treatment targ…

This study uses a survey to understand what factors influence treatment choices for Chinese patients with advanced non-small cell lung cancer and their doctors. About 590 participants (patients and physicians) will share their preferences for different aspects of first-line EGFR-…

This study is collecting blood samples and medical information from 500 adults diagnosed with lung cancer at age 45 or younger. Researchers want to understand what makes lung cancer different in younger people and find new ways to treat it. Participants will provide blood samples…

This study is for adults aged 70 and older with non-small cell lung cancer who are starting their first treatment. Researchers will observe how well standard treatments work in everyday practice, including their effects on cancer progression, side effects, and quality of life. Th…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn why some cancers respond differently to treatment. The goal is to develop more effective therapies in the future.

This study is watching how well a treatment combining amivantamab and chemotherapy works in everyday medical practice for adults with metastatic non-small cell lung cancer that has certain EGFR gene changes. About 100 people who are already getting this treatment through an early…

This study aims to understand why some cancers come back after surgery by detecting tumor cells and DNA in blood, urine, and bone marrow. Researchers will collect samples from 620 adults with various solid cancers (like lung, colon, or pancreatic cancer) and track their health ov…

This study collects and analyzes tumor tissue and blood samples from 100 people with advanced ALK-positive non-small cell lung cancer. The goal is to learn more about the biological features of the cancer and how it responds to newer targeted therapies. Participants are already p…

This observational study is exploring whether levels of a protein called Galectin-3 in the blood are linked to how well patients with kidney, lung, bladder, or liver cancer respond to immunotherapy drugs (PD-1/PDL-1 inhibitors). Researchers will measure Galectin-3 before each tre…

This study follows 130 people with a specific type of advanced lung cancer (EGFR mutation) who are starting a standard drug called osimertinib. Researchers want to see how long the drug controls the cancer in real-world settings, not just in controlled trials. Participants provid…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This observational study enrolls 38 adults with advanced ROS1-positive non-small cell lung cancer who have already taken entrectinib as part of their regular care. Researchers will analyze tumor or blood samples using genetic sequencing to understand why the cancer becomes resist…

This study uses machine learning and real-world data from over 144,000 patients to determine which treatments work best for different people with advanced non-small cell lung cancer. The goal is to tailor therapy to each patient's unique characteristics, improving survival and qu…

This study looks at whether adding a simple blood test that tracks tumor DNA (ctDNA) to regular scans can help doctors choose better treatments and improve survival. About 332 adults with advanced colorectal or non-small cell lung cancer will be randomly assigned to either standa…

This study enrolls 318 Black patients with advanced non-small cell lung cancer to see how well the drug pembrolizumab (with or without chemotherapy) works in real-world settings. Researchers will also look for biomarkers in the blood that might predict who responds best. The goal…

This study looks at 60 adults with early-stage (IB-IIIA) non-small cell lung cancer whose cancer came back after surgery and treatment with the drug osimertinib. Researchers will analyze tumor or blood samples to find genetic changes linked to the recurrence. The goal is to bette…

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, liver, stomach) who are starting immunotherapy. Researchers will track ctDNA levels in the blood to see if changes can predict early whether the treatment is working. They will also look at other m…

This study looks at using a very precise type of radiation (SBRT) a second time for lung cancer patients whose tumor has returned in the same spot. It includes 150 people who cannot have surgery and have already had SBRT once. The goal is to learn how safe and effective this seco…

This study aims to understand cancer-related fatigue in 20 people with non-small cell lung cancer who are receiving immunotherapy. Researchers will interview participants twice and use questionnaires to learn about fatigue patterns, daily life impacts, and preferences for physica…

This study looks at the gut microbiome (bacteria in your digestive system) of people with advanced non-small cell lung cancer. Researchers want to see if the types and variety of gut bacteria are linked to how well cancer treatments work and what side effects occur. About 82 part…

This study looks at why some lung cancers stop responding to targeted therapy. Researchers will take small tumor samples before and after treatment to find early signs of resistance. The goal is to develop better drug combinations that can overcome resistance. About 100 adults wi…

This study looks at how the drug osimertinib is used in everyday practice for people with a specific type of lung cancer (EGFR-mutated NSCLC) in Spain. Researchers will track about 500 patients to see how long they live, how well the drug controls the cancer, and their quality of…

This study looks at why the drug amivantamab stops working in people with a specific type of advanced lung cancer (NSCLC with EGFR exon 20 insertion). Researchers will collect blood and tumor samples from 30 patients when their disease gets worse. The goal is to find genetic chan…

This study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …

This study follows 500 adults with advanced non-small cell lung cancer who are prescribed cemiplimab (Libtayo) as part of their normal care. Researchers will track how long patients live, how their tumors respond, and any side effects. The goal is to see how well the drug works i…

This study gathers tumor samples, blood, and health information from 2,000 adults with certain lung and thymic cancers. Researchers will use these samples to study the disease's biology and find better ways to diagnose and treat it. Participants give samples and have scans, then …

This study is for people with non-small cell lung cancer who are receiving the immunotherapy drug pembrolizumab. Researchers want to see if regularly measuring the drug level in the blood can help predict how well the treatment works and reduce side effects. The study will follow…

This study is for people with non-small cell lung cancer who have had or will have surgery to remove their tumor. Researchers will collect blood samples and health information over time to see how the cancer changes and whether simple blood tests can predict if the cancer will co…

This study collects blood, urine, and bone marrow samples from 320 people with solid cancers (like lung, colon, or pancreatic cancer) and from those undergoing lung cancer screening. The goal is to detect tiny bits of tumor cells and DNA in these fluids to learn how cancer spread…

This study collects information from 550 adults with advanced lung cancer to create 'control arms'—groups that help researchers compare treatments without giving everyone a placebo. Participants receive standard therapies recommended by national guidelines. The goal is to improve…

This study compares two types of anesthesia—inhaled gas versus intravenous propofol—during surgery for early-stage non-small cell lung cancer. The goal is to see if one method leads to fewer cancer recurrences or deaths. Over 5,000 adults undergoing curative lung removal will be …

This study tests whether a natural compound called urolithin A can improve the immune response in people with solid tumors (like lung cancer or melanoma) who are starting standard immunotherapy. About 45 adults will be randomly assigned to take either urolithin A or a placebo alo…

This study tests a new way to predict how well your lungs will work after lung cancer surgery. Doctors use a 3D CT scan to create a virtual model of your lungs and simulate the surgery beforehand. The goal is to improve safety and help plan recovery. About 60 adults with non-smal…

This study aims to find biological signs of aging that can predict how older patients with lung cancer will respond to treatment. Researchers will analyze blood and tissue samples from 385 patients aged 70 and older with early-stage non-small cell lung cancer. The goal is to redu…

This study is testing a new, non-invasive technology called an electronic nose (E-nose) that analyzes chemicals in a person's breath. Researchers want to see if these breath 'fingerprints' can accurately show how well lung cancer responds to treatment and if the cancer comes back…

This study is not testing a new drug but watching how well standard treatments work for people with a specific type of lung cancer (EGFR-mutated NSCLC) in everyday medical practice. About 538 adults with advanced lung cancer will be followed to see how long they live without the …

This study aims to collect and analyze tumor tissue from 550 people with advanced non-small-cell lung cancer in Taiwan. The goal is to create a detailed map of genetic changes that drive the cancer, especially in patients whose tumors do not respond to standard targeted therapies…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…